The growing dementia prevalence in the elderly populace and the high prevalence of Alzheimer’s among people in developed countries are key factors driving the growth of this market. In addition, the launch of new drugs and the prevailing clinical trials are also resulting in robust growth of the Alzheimer’s disease therapeutics and diagnostics market.